Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05220098
Recruitment Status : Recruiting
First Posted : February 2, 2022
Last Update Posted : May 6, 2022
Sponsor:
Collaborator:
Takeda Development Center Americas, Inc.
Information provided by (Responsible Party):
Takeda

Brief Summary:

The main aim of this study is to find out the safety and tolerability of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer failing or intolerant to standard therapies. The study consists of a dose-escalation phase to determine the recommended dose of TAK-280 for the cohort-expansion phase. Cohort-expansion phase will further define the safety and initial efficacy of TAK-280.

Participants will be treated with TAK-280 for up to 14 treatment cycles for a maximum total of 56 doses of TAK-280. Each treatment cycle will be 28 days. Participants will be treated with TAK- 280 until disease progression, unacceptable toxicity, or withdrawal from study occurs. Their cancer will be treated by their doctor according to their doctor's usual clinical practice.

After the last dose of study drug, participants will be followed up for survival every 12 weeks for at least 52 weeks.


Condition or disease Intervention/treatment Phase
Unresectable Locally Advanced or Metastatic Cancer Drug: TAK-280 Phase 1 Phase 2

Detailed Description:

This study consists of 2 phases: Dose-escalation and cohort-expansion phase.

Dose-escalation phase:

Dose escalation will be conducted in participants with histologically proven, unresectable, locally advanced or metastatic cancers and the Bayesian Optimal Interval (BOIN) design will be used.

Cohort-Expansion Phase:

During the cohort-expansion phase, 5 separate participant cohorts will be enrolled, based on the tumor type. The dosing regimen used in the expansion cohorts will be the recommended phase 2 dose (RP2D) and schedule based on the safety, pharmacokinetics (PK), and antitumor activity findings from the dose-escalation phase of the study.

Enrollment into the expansion cohorts is based on a Simon 2-stage design.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 186 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Actual Study Start Date : April 22, 2022
Estimated Primary Completion Date : February 28, 2025
Estimated Study Completion Date : July 1, 2026

Arm Intervention/treatment
Experimental: TAK-280
Participants will receive TAK-280 for up to 14 treatment cycles (Each treatment Cycle = 28 days) until disease progression, unacceptable toxicity, or withdrawal from study occurs.
Drug: TAK-280
Participants will receive TAK-280 as IV infusion.




Primary Outcome Measures :
  1. Number of Participants With Treatment- emergent Adverse Events (TEAEs) [ Time Frame: Up to approximately 37 months ]
  2. Recommended Phase 2 Dose (RP2D) of TAK-280 [ Time Frame: Up to approximately 37 months ]
    The RP2D is the maximum tolerated dose (MTD) or less.

  3. Number of Participants With Dose Limiting Toxicities (DLTs) [ Time Frame: From start of the initial dose up to Cycle 1 Day 28 ]
    DLT evaluation period is defined as the time between the initial dose of TAK-280 and Cycle 1 Day 28.

  4. Maximum Tolerated Dose (MTD) of TAK-280 [ Time Frame: Up to approximately 37 months ]
    MTD is selected as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate of 30%.


Secondary Outcome Measures :
  1. Percentage of Participants With Confirmed Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (mRECIST 1.1) [ Time Frame: Up to approximately 37 months ]
  2. Duration of Response (DOR) Based on mRECIST 1.1 [ Time Frame: Up to approximately 37 months ]
  3. Progression Free Survival (PFS) [ Time Frame: From start of first dose to disease progression or death, whichever occurred first (up to approximately 37 months) ]
  4. Overall Survival (OS) [ Time Frame: From start of first dose of study drug up to death (up to approximately 37 months) ]
  5. Percentage of Participants With Prostrate Cancer (PC) Having Prostate-Specific Antigen (PSA) Reduction of >= 50% up to 6 Months [ Time Frame: Baseline up to 6 months ]
  6. Maximum Observed Plasma Concentration (Cmax) of TAK-280 [ Time Frame: Cycle 1 Day 1: 0 (Pre-dose) to 48 hours, Day 8, 15: 0 to 6 hours, Day 22: 0 to 1 hour; Cycle 2 Day 1, 8, 15, 22: 0 to 1 hour; Cycle 3 Day 1: 0 to 4 hours; Day 8, 15, 22: 0 to 1 hour; Cycle 5 Day 1: 0 to 1 hour post-dose (Each cycle = 28 days) ]
    Cmax of TAK-280 will be reported.

  7. Area Under Plasma Concentration-Time Curve (AUC) of TAK- 280 [ Time Frame: Cycle 1 Day 1: 0 (Pre-dose) to 48 hours, Day 8, 15: 0 to 6 hours, Day 22: 0 to 1 hour; Cycle 2 Day 1, 8, 15, 22: 0 to 1 hour; Cycle 3 Day 1: 0 to 4 hours; Day 8, 15, 22: 0 to 1 hour; Cycle 5 Day 1: 0 to 1 hour post-dose (Each cycle = 28 days) ]
    AUC of TAK-280 will be reported.

  8. Time to Reach Maximum Observed Plasma Concentration (tmax) of TAK-280 [ Time Frame: Cycle 1 Day 1: 0 (Pre-dose) to 48 hours, Day 8, 15: 0 to 6 hours, Day 22: 0 to 1 hour; Cycle 2 Day 1, 8, 15, 22: 0 to 1 hour; Cycle 3 Day 1: 0 to 4 hours; Day 8, 15, 22: 0 to 1 hour; Cycle 5 Day 1: 0 to 1 hour post-dose (Each cycle = 28 days) ]
    tmax of TAK-280 will be reported.

  9. Terminal Disposition Phase Half-Life (t1/2) of TAK-280 [ Time Frame: Cycle 1 Day 1: 0 (Pre-dose) to 48 hours, Day 8, 15: 0 to 6 hours, Day 22: 0 to 1 hour; Cycle 2 Day 1, 8, 15, 22: 0 to 1 hour; Cycle 3 Day 1: 0 to 4 hours; Day 8, 15, 22: 0 to 1 hour; Cycle 5 Day 1: 0 to 1 hour post-dose (Each cycle = 28 days) ]
    t1/2 of TAK-280 will be reported.

  10. Total Clearance (CL) of TAK-280 [ Time Frame: Cycle 1 Day 1: 0 (Pre-dose) to 48 hours, Day 8, 15: 0 to 6 hours, Day 22: 0 to 1 hour; Cycle 2 Day 1, 8, 15, 22: 0 to 1 hour; Cycle 3 Day 1: 0 to 4 hours; Day 8, 15, 22: 0 to 1 hour; Cycle 5 Day 1: 0 to 1 hour post-dose (Each cycle = 28 days) ]
    CL of TAK-280 will be reported.

  11. Volume of Distribution at Steady State After Intravenous Administration (Vss) of TAK-280 [ Time Frame: Cycle 1 Day 1: 0 (Pre-dose) to 48 hours, Day 8, 15: 0 to 6 hours, Day 22: 0 to 1 hour; Cycle 2 Day 1, 8, 15, 22: 0 to 1 hour; Cycle 3 Day 1: 0 to 4 hours; Day 8, 15, 22: 0 to 1 hour; Cycle 5 Day 1: 0 to 1 hour post-dose (Each cycle = 28 days) ]
    VSS of TAK-280 will be reported.

  12. Percentage of Participants who Develop Cytokines for TAK-280 [ Time Frame: Cycle 1 to 5: pre-dose (Each cycle= 28 days) ]
    Percentage of participants who develop cytokines for TAK-280 will be reported.

  13. Percentage of Participants who Develop Positive Induced Antidrug Antibody (ADA) for TAK-280 [ Time Frame: Cycle 1 to 5: pre-dose (Each cycle= 28 days) ]
    Percentage of participants who develop positive induced ADA for TAK-280 will be reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Age greater than or equal to (>=)18 years.
  • Criteria for disease state.

    1. Dose-escalation tumor histologies: Dose escalation will begin by initially enrolling participants with histologically or pathologically confirmed, unresectable, locally advanced or metastatic cancers.
    2. Cohort-expansion tumor histologies: Participants will be eligible if they have histologically proven, unresectable, locally advanced or metastatic malignant neoplasms.
  • Eastern Cooperative Oncology Group performance status (less than or equal to [<=]) 1.
  • Measurable disease per modified Response Evaluation Criteria in Solid Tumors (mRECIST) Version 1.1 and documented by CT and/or MRI except for participants with PC with only bone metastases.

Exclusion Criteria

  • History of known autoimmune disease.
  • Major surgery or traumatic injury within 8 weeks before the first dose of TAK-280.
  • Unhealed wounds from surgery or injury.
  • Ongoing or active infection of Grade >=2.
  • Oxygen saturation < 92% on room air at screening or during C1D1 predose assessment.
  • Inflammatory process that has not resolved >= 4 weeks before the first dose of study drug. participants with chronic low-grade inflammatory processes such as radiation-induced pneumonitis are excluded regardless of their duration.
  • Vaccination with any live virus vaccine within 4 weeks or other vaccines within 2 weeks before the initiation of study drug. Inactivated annual influenza vaccination is allowed.
  • Known hypersensitivity to TAK-280 or any excipient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05220098


Contacts
Layout table for location contacts
Contact: Takeda Contact +1-877-825-3327 medinfoUS@takeda.com

Locations
Layout table for location information
Australia
Monash Medical Centre Recruiting
Clayton, Australia, 3168
Contact: Site Contact       sophia.frentzas@monashhealth.org   
Principal Investigator: Sophia Frentzas, MD         
Sponsors and Collaborators
Takeda
Takeda Development Center Americas, Inc.
Investigators
Layout table for investigator information
Study Director: Study Director Takeda
Additional Information:
Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT05220098    
Other Study ID Numbers: TAK-280-1501
First Posted: February 2, 2022    Key Record Dates
Last Update Posted: May 6, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
URL: https://vivli.org/ourmember/takeda/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms
Neoplasms, Second Primary
Neoplastic Processes
Pathologic Processes